March 02, 2026 — 1 articles reviewed
This cycle’s coverage centered on a single but important theme: the longitudinal relationship between regular cannabis use and anxiety outcomes. A decade-long Canadian cohort study drew attention for its dose-dependent findings linking frequent cannabis use to increased anxiety risk in vulnerable populations.
Short-term relief is not the same as long-term safety, and this study is a strong reminder that patient selection and dosing discipline are not optional in cannabis medicine. When patients tell us cannabis “helps their anxiety,” our job is to hold space for that experience while also ensuring they understand what the longitudinal evidence actually shows.
Digest-Level Clinical Commentary
Clinical Reflection
The emerging longitudinal evidence from Canadian cohort data reinforces what I’m observing clinically: that dose and frequency of cannabis use demonstrate a concerning dose-dependent relationship with anxiety progression in regular users, which challenges the common patient narrative that cannabis reliably manages anxiety symptoms. This finding suggests I need to be more rigorous in distinguishing between acute anxiolytic effects some patients report and the paradoxical long-term anxiety outcomes documented in prospective studies, particularly when counseling patients about chronic use patterns. Going forward, I’m emphasizing lower-frequency dosing strategies and CBT integration for my patients with anxiety rather than defaulting to cannabis as monotherapy.
Clinical Perspective
Recent longitudinal evidence continues to document a dose-dependent association between regular cannabis use and increased anxiety symptoms, reinforcing existing clinical observations about potential psychiatric risks with frequent consumption. These findings underscore the importance of screening cannabis use patterns during anxiety assessments and counseling patients—particularly those with baseline anxiety vulnerability—about cumulative exposure risks. As cannabis legalization expands access, clinicians should remain attentive to distinguishing between acute anxiety effects and longer-term neurobiological changes that may alter treatment approaches for affected patients.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: